Treatment of Depression with Botulinum Toxin A: A Case Series : Dermatologic Surgery

Secondary Logo

Journal Logo

ORIGINAL ARTICLE

Treatment of Depression with Botulinum Toxin A

A Case Series

FINZI, ERIC MD, PhD*,†; WASSERMAN, ERIKA PhD

Author Information
Dermatologic Surgery 32(5):p 645-649, May 2006.

Abstract

BACKGROUND 

Major depression is a common and serious disease that may be resistant to routine pharmacologic and psychotherapeutic treatment approaches.

OBJECTIVE 

To evaluate the efficacy of botulinum toxin A treatment of glabellar frown lines in treating patients with major depression, using a small open pilot trial.

METHODS 

Patients who met DSM-IV criteria for ongoing major depression in spite of pharmacologic or psychotherapeutic treatment were evaluated with the Beck Depression Inventory II (BDI-II) before receiving botulinum toxin A to their glabellar frown lines. Two months later, all patients were re-evaluated clinically and with the BDI-II.

RESULTS 

Ten depressed patients were treated with botulinum toxin A, and 9 of 10 patients were no longer depressed 2 months after treatment. The tenth patient had an improvement in mood.

CONCLUSION 

To our knowledge, these are the first reported cases of depression treated with botulinum toxin A.

© 2006 by the American Society for Dermatologic Surgery, Inc.

You can read the full text of this article if you:

Access through Ovid